目的:以24h动态血压监测评价"活血散风、平肝降逆"针法治疗轻、中度原发性高血压患者的疗效.方法:选择107例轻、中度高血压患者,予以"活血散风、平肝降逆"针法治疗4周,分别于治疗前后行24h动态血压监测并计算其谷峰比值、平滑指数后进行比较分析.结果:治疗4周后24h平均收缩压、舒张压;日间平均收缩压、舒张压;夜间平均收缩压、舒张压与治疗前比较,均有显著性降低(P＜0.05),收缩压、舒张压负荷也有显著降低(P＜0.05).收缩压谷峰比值为76%,舒张压谷峰比值72%,收缩压平滑指数为(1.34±0.13),舒张压平滑指数为(1.26±0.22).结论:"活血散风、平肝降逆"针法具有良好的降压效果及满意的谷峰比值、平滑指数,临床应用安全.

This work aimed to evaluate the antihypertensive effects of acupuncture on patients with mild to moderate essential hypertension by 24 h ambulatory blood pressure monitoring (ABPM). Fifty patients with mild to moderate essential hypertension were treated with 80 mg telmisartan, once a day for 4 weeks. 24 h ABPM was performed before and after the treatment, and the trough/peak ratio and smoothness index were calculated. The mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) in 24 h, day time and night time, had a significant reduction（P<0.05）. The blood pressure loads of SBP and DBP were also significantly decreased（P<0.05）. The trough/peak ratio of SBP was 76%, and that of DBP was 72%. The smoothness index of SBP was 1.34±0.13, and that of DBP was 1.16±0.22. The results showed that compound telmisartan is an effective and safe antihypertensive drug with the satisfactory trough/peak ratio and smoothness index.

科学技术部“重大新药创制”科技重大专项（2009ZX09502-014）：基于脑病治疗的中药复方药理学及药效学评价关键技术研究，负责人：李澎涛；科学技术部国家“十一五”支撑计划（2006BAI08B05-04）：基于脑微血管内皮细胞功能物质发现的脑病药物筛选与效应分析新技术，负责人：潘彦舒；教育部科学技术研究重点项目（109023）从内皮-胶质细胞信息网络解析脑络功能及其病理基础，负责人：李卫红。